ASH 2025 Archives - Page 2 of 2 - SOHO Insider

Skip to content

Dr. Kelly Bolton on ivosidenib in IDH1-mutated CCUS
Talquetamab, teclistamab combo induces responses in patients with extramedullary myeloma
Dr. Manali Kamdar to give free virtual CAR-T talk at 4:30 pm CT on Jan. 20
FDA clears IND for KLN-1010 in relapsed or refractory myeloma
Advances in essential thrombocythemia with Drs. Kuykendall, Tremblay

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Pearl van Heteren, MD, on the DALY 2-EU trial in R/R DLBCL

Cellular Therapy

Pearl van Heteren, MD, on the DALY 2-EU trial in R/R DLBCL

Leukemia

Pearl van Heteren, MD, on the DALY 2-EU trial in R/R DLBCL

Lymphoma

Pearl van Heteren, MD, on the DALY 2-EU trial in R/R DLBCL

Multiple Myeloma

Pearl van Heteren, MD, on the DALY 2-EU trial in R/R DLBCL

Myelodysplastic Syndromes

Pearl van Heteren, MD, on the DALY 2-EU trial in R/R DLBCL

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

January 21, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Meetings / Conferences ASH 2025

ASH 2025

The 67th ASH Annual Meeting & Exposition was held on December 6-9, 2025, at Orlando’s Orange County Convention Center.

Pearl Van Heteren

ASH 2025 Lymphoma Aggressive B-Cell Lymphomas

Pearl van Heteren, MD, on the DALY 2-EU trial in R/R DLBCL

by SOHO Insider Editors
December 30, 2025
0 Comments

ASH 2025 News

DOCK1 inhibition in TP53-mutant clonal hematopoiesis

by SOHO Insider Editors
December 21, 2025
0 Comments

ASH 2025 Leukemia Acute Myeloid Leukemia

Dr. Gruenbaum, of Blood Cancer United, discusses menin inhibitors in AML

by SOHO Insider Editors
December 17, 2025
0 Comments

blood draw

ASH 2025

Updated phase 3 VERIFY results confirm rusfertide significantly improves PV outcomes over SOC

by Leah Sherwood
December 16, 2025
0 Comments

ASH banner

ASH 2025 Lymphoma Indolent B-Cell Lymphomas

Epcoritamab triplet may set new standard in 2L follicular lymphoma

by Leah Sherwood
December 12, 2025
0 Comments

Update

ASH 2025 Leukemia Chronic Lymphocytic Leukemia Meetings / Conferences News

Phase 3 study finds fixed-duration treatment non-inferior to continuous treatment in CLL

by Kerri Fitzgerald
December 7, 2025
0 Comments

ASH 2025 Lymphoma News

Extended MorningSun study results show ‘promising’ survival with subcutaneous mosunetuzumab

by Kerri Fitzgerald
December 6, 2025
0 Comments

pen check

ASH 2025 Multiple Myeloma News

Pre-apheresis lenalidomide improves T-cell fitness in patients with myeloma undergoing transplant

by Kerri Fitzgerald
December 6, 2025
0 Comments

ASH 2025 Multiple Myeloma News

Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma

by Kerri Fitzgerald
December 6, 2025
0 Comments

1
2

Top Categories

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Cellular Therapy

45

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Leukemia

77

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Lymphoma

80

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Multiple Myeloma

72

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Myelodysplastic Syndromes

27

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Myeloproliferative Neoplasms

15

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Cellular Therapy

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Leukemia

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Lymphoma

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Multiple Myeloma

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Myelodysplastic Syndromes

$Investigational bispecific antibody shows ‘encouraging’ antitumor activity in relapsed/refractory myeloma$

Myeloproliferative Neoplasms

Subscribe

Recent Posts

SOHO Insider

Dr. Kelly Bolton on ivosidenib in IDH1-mutated CCUS

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Talquetamab, teclistamab combo induces responses in patients with extramedullary myeloma

Expanding access to CAR-T

Dr. Manali Kamdar to give free virtual CAR-T talk at 4:30 pm CT on Jan. 20

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.